Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

Rhea-AI Summary

Haisco and AbbVie (NYSE: ABBV) entered an exclusive license agreement announced April 10, 2026, covering multiple pain compounds.

Haisco granted AbbVie global development, manufacturing, and commercialization rights excluding mainland China, Hong Kong, and Macau. Haisco will receive an upfront payment of USD $30 million, up to USD $715 million in milestones, and tiered royalties on future net sales.

Positive

• Upfront payment of USD $30 million
• Potential USD $715 million in development and commercial milestones
• Exclusive global rights granted to AbbVie outside China regions
• Pipeline includes multiple compounds across preclinical to Phase 1
• Leverages AbbVie development and commercialization expertise

Negative

• Programs are preclinical to Phase 1, implying high clinical risk
• Haisco granted AbbVie exclusive rights outside China, limiting direct global sales

News Market Reaction – ABBV

-0.71%

-0.71% Session close to close

In the Apr 13 session, ABBV declined 0.71%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement adds a new pain-focused collaboration where AbbVie gains global rights (excluding ...

Analysis

This announcement adds a new pain-focused collaboration where AbbVie gains global rights (excluding certain China territories) to multiple compounds spanning preclinical to Phase 1 stages. Economics include a $30 million upfront, up to $715 million in milestones, and tiered royalties. Investors may contextualize this against AbbVie’s existing neuroscience focus, recent guidance changes tied to R&D charges, and upcoming earnings, watching for future clinical updates and regulatory milestones on these assets.

Key Figures

Upfront payment: USD $30 million Milestone potential: USD $715 million

2 metrics

Upfront payment USD $30 million Exclusive license agreement for pain medicines

Milestone potential USD $715 million Aggregate development, regulatory, commercial milestones

Historical Context

5 past events · Latest: Apr 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 08	Brand grant program	Positive	+2.5%	BOTOX Cosmetic reopened The Confidence Collective with grants to women entrepreneurs.
Apr 07	Training center launch	Positive	-0.1%	Allergan Aesthetics opened a new AMI Austin training facility in the U.S.
Mar 31	Promotional campaign	Positive	+2.0%	Fourth annual CoolMonth promotion with CoolSculpting discounts and giveaways.
Mar 31	Correction release	Positive	+2.0%	Correction related to CoolMonth promotion and CoolSculpting discount campaign.
Mar 31	Earnings call notice	Neutral	+2.0%	Announcement of Q1 2026 earnings release and conference call timing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent brand and commercial initiatives have often coincided with modestly positive price reactions, though not uniformly.

Recent Company History

Over the last few weeks, AbbVie news flow has centered on aesthetics brands and corporate events. BOTOX Cosmetic’s “The Confidence Collective” grant program on Apr 8 and CoolSculpting “CoolMonth” promotions on Mar 31 both aligned with gains around +2%. The opening of the AMI Austin training center on Apr 7 saw a slight decline. An upcoming Q1 2026 earnings call on Apr 29 was also announced. Today’s licensing deal adds a neuroscience/pain pipeline dimension to that largely commercial narrative.

Key Terms

exclusive licensing agreement, preclinical, phase 1 clinical development, tiered royalties

4 terms

exclusive licensing agreement financial

"announced that it has entered into an exclusive licensing agreement with AbbVie"

An exclusive licensing agreement is a legal deal where the owner of an asset—like a drug formula, technology, or brand—gives one other party the sole right to use, sell, or develop that asset in a defined territory or field. For investors, exclusivity can act like a temporary monopoly: it can boost revenue and competitive edge by preventing rivals from using the same asset, but it also concentrates risk on the licensee’s success and the terms of payments or milestones.

preclinical medical

"development stages in China, ranging from preclinical to Phase 1 clinical development"

Preclinical describes the stage of drug or medical-product development when researchers test a candidate in the lab and in animals to see if it is safe, reaches intended targets, and shows basic effectiveness before any human trials begin. For investors, preclinical status signals an early, higher‑risk opportunity where positive lab results can increase value but significant work, time, and regulatory hurdles remain — like proofing a prototype in a workshop before road testing.

phase 1 clinical development medical

"ranging from preclinical to Phase 1 clinical development"

Phase 1 clinical development is the first stage of testing a new drug or medical treatment in people, typically involving a small group to check safety, how the body processes the treatment, and to identify common side effects. For investors, it matters because successful Phase 1 results reduce early risk, validate basic safety and dosing, and create the first clinical evidence that a program can advance—key milestones that influence funding, valuation and future trial timelines.

tiered royalties financial

"In addition, Haisco is eligible to receive tiered royalties on future net sales."

Tiered royalties are a payment structure where the percentage of earnings paid as royalties changes based on different levels of sales or production. For example, a company might pay a smaller percentage on initial sales and a higher percentage as sales increase beyond certain points. This system encourages higher sales by adjusting payments, making it important for investors to understand how revenue sharing may vary as a product or project grows.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BEIJING, April 13, 2026 /PRNewswire/ -- On April 10, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with AbbVie (NYSE: ABBV), a global biopharmaceutical company. Under the agreement, Haisco grants AbbVie the exclusive rights to develop, manufacture, and commercialize novel medicines for the treatment of pain globally, excluding mainland China, Hong Kong, and Macau.

The program includes multiple compounds designed to address pain-related indications. These compounds are currently at various development stages in China, ranging from preclinical to Phase 1 clinical development.

"This collaboration is highly aligned with our international development strategy and is expected to generate sustainable value and long-term returns," said Dr. Pangke Yan, chief executive officer of Haisco. "By partnering with a global biopharmaceutical leader such as AbbVie, Haisco aims to accelerate the global development of innovative pain therapies and deliver high-quality treatment options to patients worldwide."

The collaboration strengthens Haisco's global presence and pipeline by leveraging AbbVie's development and commercialization capabilities, as well as its recognized expertise in neuroscience.

Haisco will receive an upfront payment of USD $30 million and is eligible to receive up to USD $715 million in aggregate development, regulatory, and commercial milestone payments. In addition, Haisco is eligible to receive tiered royalties on future net sales.

About Haisco

As a benchmark enterprise in China's innovative pharmaceutical sector, Haisco adheres to a core strategy of "innovation-driven growth and global expansion." The company has established a diversified R&D pipeline encompassing small-molecule innovative drugs, biologics, and high-end generics. Haisco is actively advancing more than 50 R&D programs across key therapeutic areas including pain management, oncology, respiratory diseases, autoimmune disorders, metabolic diseases, and central nervous system disorders; notably, over 10 of these programs have entered pivotal clinical stages. The company has maintained a strong commitment to R&D, with investment exceeding 15% of revenue in each of the past three years. It has established major R&D centers in Chengdu, Shanghai, and Silicon Valley, supported by a research team with extensive global experience, forming an integrated innovation system combining in-house capabilities and external collaboration.

As early as 2015, Haisco initiated its global strategy and has since actively expanded into international markets through multiple approaches, including out-licensing transactions, co-development partnerships, and overseas mergers and acquisitions.

Looking ahead, Haisco will continue to focus on areas of unmet medical need, strengthen its capabilities in independent innovation and global collaboration, and strive to deliver high-quality, China-originated innovative medicines to patients around the world.

View original content:https://www.prnewswire.com/news-releases/haisco-enters-into-exclusive-license-agreement-with-abbvie-to-develop-novel-medicines-for-pain-302740226.html

SOURCE Haisco

FAQ

What did AbbVie (ABBV) agree with Haisco on April 10, 2026?

AbbVie secured an exclusive global license to develop and commercialize Haisco pain compounds outside China regions. According to Haisco, the deal covers multiple compounds at preclinical to Phase 1 stages and transfers global development and commercialization rights to AbbVie.

How much did Haisco receive from AbbVie in the April 2026 deal with ABBV?

Haisco received an upfront payment of USD $30 million from AbbVie. According to Haisco, the company may also receive up to USD $715 million in milestone payments plus tiered royalties on future net sales.

What parts of the world are excluded from AbbVie's ABBV license with Haisco?

The license excludes mainland China, Hong Kong, and Macau from AbbVie's rights. According to Haisco, AbbVie holds exclusive rights to develop, manufacture, and commercialize the programs globally except for those specified China regions.

What development stages are the Haisco pain compounds under in the ABBV agreement?

The programs range from preclinical to Phase 1 development at the time of the agreement. According to Haisco, the compounds are at various early-stage development stages in China, implying ongoing clinical work and risk.

How could the ABBV licensing deal affect Haisco's global strategy?

The deal is positioned to accelerate global development and expand Haisco's international presence via AbbVie's capabilities. According to Haisco, the collaboration leverages AbbVie's neuroscience and commercialization expertise to advance pain therapies worldwide.